Uncommon Conversations by Worldwide Clinical Trials

Co-Founder and COO of Compass Pathways, Lars Wilde, discusses his journey to secure funding for his psilocybin therapy for treatment-resistant depression. What made him so successful? Listen now to find out.

Investors expressed two risks to Peter Strumph regarding his pitch. In this episode, Peter talks about how he addressed and overcame these risks during funding conversations, and the lessons he learned along the way.

In this episode, Peter reveals what surprised him most: the buzz surrounding innovation. So many people claim that it makes or breaks a funding deal, but does it? Peter talks about how he approached this when preparing his funding strategy.

What kind of presentation intrigues investors? What parts of Peter’s presentation were so successful? Uncover how one pharmaceutical executive created a presentation that ultimately won the business of investors.

Meghann Howland, Vice President, Therapeutic Strategy Lead, Oncology, at Worldwide Clinical Trials, discusses the challenges of managing an early phase oncology clinical trial, and how the right contract research organization (CRO) can be a valuable asset.

The scientific, medical, and operational experts at Worldwide Clinical Trials’ have been leading Alzheimer’s disease research since the advent of cholinesterase inhibitors as a cognitive therapeutic in the late 1970s. It’s been a long road on the way to finding a cure for Alzheimer’s disease and related dementias. And we’re not about to give up … Continue reading Alzheimer’s Disease: We’re Not About to Give Up Now →

Early phase research involves constantly moving elements, including toxicology results, regulatory requirements, program optimization, study design strategy and drug readiness. Initial human data are a critical development milestone. Our early phase experts work as an extension of your team, to provide tactical options tailored to your asset’s early development, guiding you to proof-of-concept swiftly, with … Continue reading The Key to Conducting a Successful Early Phase Clinical Trial →